New Chairman and extended board at Isofol Medical AB (publ)
Isofol Medical AB (publ), developing arfolitixorin as treatment for advanced colorectal cancer is calling an Extraordinary General Meeting on Wednesday 10 October. The present Chairman, Jan-Eric Österlund, is resigning and the Nomination Committee is proposing Dr Ulf Jungnelius as new Chairman. The Committee is also proposing an increased board with three new directors.Isofol’s present Chairman, Jan-Eric Österlund, has asked to resign due to personal reasons. Jan-Eric has been Chairman since 2012. During his time as chairman Isofol has been transformed from a research company into a